MiNK Therapeutics 1 article

Invariant natural killer T-cell therapy is the principal modality behind MiNK Therapeutics. As an allogeneic invariant-NKT cell therapy company developing off-the-shelf cellular immunotherapies, it combines that approach with allogeneic iNKT cell platform and agenT-797 off-the-shelf iNKT cells, separating the company from noncellular therapeutics. Taken together, hematologic cancer cellular therapy and CAR-iNKT engineering platform provide additional company-level context without turning a product name, target or platform into a synonym for MiNK Therapeutics.

Biotechnology News & Analysis

October 3, 2026, 7:33 AM · 4 mins read

CaseBioscience joins ARPA-H team to break cold-chain barrier in cell therapy

CaseBioscience is now part of a Likarda-led group with up to $7.3 million from ARPA-H. The goal: make it possible to store and ship cell therapies at room temperature, ending the cold-chain bottleneck.